Predicting Clinical GI Safety Outcomes Using an In Vitro Human Intestinal Epithelial Model

Presented By: Bailey Zwarycz, PhD Speaker Biography: Bailey is currently the Associate Director of Scientific Business Development at Altis Biosystems. She received her Ph.D. from the University of North Carolina at Chapel Hill, mentored by Dr. Scott Magness. During her doctoral research, Bailey developed expertise in intestinal stem cell biology by investigating intestinal stem cell dynamics in response to environmental cues, including extracellular matrices and inflammatory cytokines... Webinar: Predicting Clinical GI Safety Outcomes Using an In Vitro Human Intestinal Epithelial Model Webinar Abstract: The gastrointestinal (GI) epithelium is the body’s first line of defense to luminal contents such as food, microbiota, pharmaceuticals, and toxins. A small pool of proliferative stem and progenitor cells are responsible for maintaining and repairing the entire GI epithelium. Oncology chemotherapeutics target these rapidly dividing cells, contributing to adverse event risks, with 50-80% of patients developing diarrhea. Historically, these compounds have the lowest overall success rate for regulatory approval... LabRoots on Social: Facebook:   / labrootsinc   Twitter:   / labroots   LinkedIn:   / labroots   Instagram:   / labrootsinc   Pinterest:   / labroots   SnapChat: labroots_inc